Medicare AdvantagePrior AuthMedium impact
Cotellic (cobimetinib) (Revised)
Humana·Oncology, Dermatology·Medicare Advantage
Effective date
Jan 1, 2026
We identified it
Jun 24, 2026
Summary
Humana Medicare Advantage has revised prior authorization requirements for Cotellic (cobimetinib) for melanoma and histiocytic neoplasms. The policy requires specific BRAF mutation documentation for melanoma and prohibits combination with certain immunotherapy drugs.
Action Required
Before January 1, 2026: Billing team must ensure prior authorization is obtained for all Cotellic (cobimetinib) prescriptions for Humana Medicare Advantage members. Providers must document BRAF V600 mutation for melanoma patients and ensure combination therapy requirements are met. Update prior authorization checklists to include exclusion criteria for concomitant immunotherapy drugs.